Thursday, November 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 26, 2026

If You Own One of These ETFs, Fidelity Is About to Charge You $100 to Trade It

View original at finance.yahoo.com
If You Own One of These ETFs, Fidelity Is About to Charge You $100 to Trade It Starting June 1, Fidelity will charge a $100 fee on purchase trades on more than 120 exchange-traded funds (ETFs)…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Fidelity is telling ETF issuers to subsidize the platform fee or investors will be charged $100 every time they purchase shares of the affected ETFs.

    60% confidence
  • Fidelity's decision to charge a $100 fee on ETF purchases is one of the most investor-unfriendly decisions seen in a while.

    60% confidence
  • Fidelity is not threatening to remove affected ETFs from its platform, but is making investing in them less attractive.

    60% confidence
  • It is not the ETF issuers who will suffer immediately from Fidelity's fee; it will be investors who want to buy shares of the affected ETFs.

    60% confidence
  • While trades are free for investors on many platforms, they still cost money for brokerage platforms, and many ETF issuers subsidize the fee themselves so that funds remain accessible.

    60% confidence
  • Fidelity's fee policy immediately makes Vanguard look more attractive as a competing platform.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com